



Amarin Corporation plc  
 Investor Relations Department  
 2 Pembroke House, Upper  
 Pembroke  
 Street 28-32  
 Dublin 2  
 Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AMRN**

Last Trade:	3.06
Trade Time:	3:59 PM ET May 22, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.66 - 4.60
Volume	N/A

Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- May 2, 2018*  
[Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations](#)
- Apr 26, 2018*  
[Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018](#)
- Apr 23, 2018*  
[Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer](#)
- Apr 12, 2018*  
[Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions](#)
- Apr 12, 2018*  
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides](#)

**Financials** [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 27, 2018*  
[Annual Report \(10-K\)](#)
- Apr 20, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- May 2, 2018*  
[Quarterly Report \(10-Q\)](#)
- Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)